论文部分内容阅读
目的探讨急性白血病膜Fas(mFas)及血清可溶性Fas(sFas)表达的意义。方法应用免疫组化SABC法和双抗夹心酶联免疫吸附试验法(ELISA),于2001-112002-09对滨州医学院附属医院的30例急性白血病患者检测骨髓细胞mFas抗原及血清sFas的表达,与正常对照组比较,并分析sFas与治疗效果的关系。结果骨髓细胞mFas抗原阳性表达率在急性淋巴细胞白血病(ALL)为(5·62±2·27)%,急性非淋巴细胞白血病(ANLL)为(8·80±4·15)%,均低于正常对照组(28·75±11·20)%(P<0·01);化疗前血清sFas在ALL为(7·92±2·36)μg/L,ANLL为(8·79±3·12)μg/L,均高于正常对照组;CR组化疗后血清sFas[(4·08±2·24)μg/L]较化疗前[(7·85±1·96)μg/L]显著降低(P<0·01)。结论mFas下调及血清sFas升高所致的Fas/FasL凋亡途径障碍可能参与急性白血病的发病,血清sFas可作为急性白血病观察疗效、判断预后的参考指标。
Objective To investigate the significance of the expression of Fas (mFas) and soluble Fas (sFas) in acute leukemia. Methods The expression of mFas antigen and sFas in bone marrow cells was detected by immunohistochemical SABC method and double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) in 2001-112002-09 in 30 cases of acute leukemia in Binzhou Medical College Affiliated Hospital. Compared with normal control group, the relationship between sFas and therapeutic effect was analyzed. Results The positive rate of mFas antigen in bone marrow cells was (5.22 ± 2.27)% in acute lymphoblastic leukemia (ALL) and (8 · 80 ± 4.15)% in acute non-lymphocytic leukemia (ALLLL) (28 · 75 ± 11 · 20)% (P <0.01) in the normal control group. The serum levels of sFas in the patients before chemotherapy were (7.292 ± 2.36) μg / L ALL and (8 · 79 ± 3) · (12) μg / L, all higher than that in the normal control group; the serum sFas level in the CR group after chemotherapy was (4. 08 ± 2.24) μg / L compared with [ ] Was significantly lower (P <0.01). Conclusion The down-regulation of mFas and the increase of serum sFas may result in the pathogenesis of acute leukemia. FasL / FasL pathway may be involved in the pathogenesis of acute leukemia. Serum sFas can be used as a reference for evaluating the prognosis of patients with acute leukemia.